News | June 15, 2012

Naviscan PEM Research Presented At SNM 2012

Studies focused on novel radiotracers, new applications and clinical validation of low-dose positron emission mammography

June 15, 2012 — Several groundbreaking studies on the Naviscan PET scanner, the breast application for which is positron emission mammography (PEM), were presented this week at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, Fla. Researchers from the Johns Hopkins University, Thomas Jefferson University, Boston University and University of Washington presented abstracts focusing on use of novel radiotracers, new clinical applications as well as low-dose imaging with PEM. 

Mathew Thakur, M.D., from Thomas Jefferson University presented results of an ongoing head-to-head comparison of 18F-FDG with a novel low-dose radiotracer Cu-64-TP3805 (NuView Life Sciences, Park City, UT) demonstrating concordance. This is significant since the dose from Cu-64 is similar to one mammogram and does not require fasting indicating a potential for PEM to be used in a screening capacity. Richard Wahl, M.D. of Johns Hopkins University presented results on feasibility of using the technology for metabolic assessment and evaluation of treatment response for patients with osteoarthritis. Gustavo Mercier, M.D. from Boston University and Lawrence MacDonald from University of Washington shared clinical and research validations of performing PEM imaging using 50 percent less radiation. 

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term “specificity.” Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only U.S. Food and Drug Administration-cleared, CE-certified 3D molecular breast imaging (MBI), device on the market with biopsy-guidance. 

For more information: www.naviscan.com 

Related Content

HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.

Getty Images

News | PET Imaging | September 14, 2020
September 14, 2020 — To meet the pressing need to better understand the prevalence, progression, and clinical impact
a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology

a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Radiology Imaging | August 14, 2020
August 14, 2020 — According to ARRS' ...
Hologic, Inc. launched the Back to Screening campaign encouraging women to schedule their annual mammograms now that healthcare facilities across the nation are re-opening their doors following closures due to the COVID-19 pandemic.

Nine-time GRAMMY Award winner and breast cancer survivor Sheryl Crow has served as the spokesperson for Hologic’s Genius 3D Mammography exam for nearly five years.

News | Breast Imaging | August 03, 2020
August 3, 2020 — Hologic, Inc. launched the Back to Screening campaign encouraging women to schedule their ann
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...
Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle

Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

News | PET Imaging | July 16, 2020
July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have b